Drug Trial Radar · NCT01496313
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Jun 8, 2012
Primary completion
Apr 2, 2014
Study completion Jul 11, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds. It will also help the investigators understand the side effects of different doses in these patients.
Conditions
- Thyroid Cancer
Interventions
300mg vandetanibDrug
Oral blinded tablets taken once daily. At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment Dosing with unblinded study treatment can continue until 24 months after patient was randomised. At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
150mg vandetanibDrug
Oral blinded tablets taken once daily. At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg Dosing with unblinded study treatment can continue until 24 months after patient was randomised At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the InvestigatorTime frame: Randomisation to week 60 (maximum)
Locations
30 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Houston, Texas
Investigational Site Number : 1903
Olomouc, Czechia
Research Site
Olomouc, Czechia
Investigational Site Number : 1901
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Bangalore Karnataka, India
Research Site
Vellore, India
Research Site
Beersheba, Israel
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Petah Tikva, Israel
Research Site
Catania, Italy
Research Site
Milan, Italy
Research Site
Palermo, Italy
Research Site
Pisa, Italy
Research Site
Roma, Italy
Research Site
Siena, Italy
Research Site
Torino, Italy
Research Site
Groningen, Netherlands
Research Site
Leiden, Netherlands
Investigational Site Number : 5703
Gliwice, Poland
Research Site
Gliwice, Poland
Research Site
Warsaw, Poland
Research Site
Zgierz, Poland
Investigational Site Number : 5704
Warsaw, Masovian Voivodeship, Poland
Research Site
Saint Petersburg, Russia
Research Site
Cardiff, United Kingdom
Research Site
Greater London, United Kingdom
Research Site
London, United Kingdom
Research Site
Tyne & Wear, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.